Skip to main content

Table 2 Results of fixed-effect network meta-analysis and comparison with previous network meta-analysis by Rodgers et al., 2011[16]

From: Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

   Placebo Adalimumab 40 mg/2 weeks Infliximab 5 mg/kg/8 weeks Golimumab 50 kg/4 weeks Etanercept 2x25 mg/week
PsARC response: Odds ratio versus placebo OR (95% CrI) NA 4.28 (2.83, 6.57) 9.97 (5.95, 17.08) 10.33 (5.84, 19.04) 7.74 (4.5, 13.67)
Probability (95% CrI)+ 0.26 (0.22, 0.29) 0.59 (0.48, 0.70) 0.77 (0.66, 0.86) 0.78 (0.66, 0.87) 0.73 (0.60, 0.83)
Comparison with Rodgers 2011 [12] 0.25 (0.18, 0.32) 0.59 (0.44, 0.71) 0.80 (0.67, 0.89) NA 0.71 (0.57, 0.83)
Change in HAQ conditional on PsARC response WMD versus placebo non-responders | PsARC responders (95% CrI)* -0.26 (-0.32, -0.21) -0.49 (-0.58, -0.40) -0.66 (-0.77, -0.55) -0.44 (-0.59, -0.29) -0.64 (-0.77, -0.51)
Comparison with Rodgers 2011 [12] -0.24 (-0.34, -0.15) -0.48 (-0.60, -0.35) -0.66 (-0.79, -0.52) NA -0.63 (-0.81, -0.46)
WMD versus placebo non-responders | PsARC non-responders (95% CrI)* NA -0.14 (-0.24, -0.03) -0.20 (-0.31, -0.08) -0.06 (-0.18, 0.06) -0.20 (-0.35, -0.050)
  Comparison with Rodgers 2011 [12] NA -0.13 (-0.26, -0.00) -0.19 (-0.33, -0.06) NA -0.19 (-0.381, 0.00)
PASI50 Probability (95% CrI)+ 0.12 (0.09, 0.16) 0.71 (0.51, 0.86) 0.90 (0.80, 0.96) 0.71 (0.50, 0.87) 0.40 (0.16, 0.73)
  Comparison with Rodgers 2011 [12] 0.13 (0.09,0.18) 0.74 (0.55,0.88) 0.91 (0.82,0.97) NA 0.40 (0.24,0.59)
PASI75 Probability (95% CrI)+ 0.05 (0.03, 0.07) 0.47 (0.27, 0.68) 0.77 (0.59, 0.89) 0.46 (0.26, 0.70) 0.19 (0.06, 0.49)
  Comparison with Rodgers 2011 [12] 0.04 (0.03,0.07) 0.48 (0.28,0.69) 0.77 (0.59,0.90) NA 0.18 (0.09,0.31)
PASI90 Probability (95% CrI)+ 0.02 (0.01, 0.03) 0.24 (0.12, 0.44) 0.54 (0.34, 0.75) 0.23 (0.11, 0.46) 0.08 (0.02, 0.26)
  Comparison with Rodgers 2011 [12] 0.02 (0.01,0.03) 0.26 (0.12,0.45) 0.56 (0.35,0.77) NA 0.07 (0.03,0.15)
  1. CrI, credible interval (Bayesian probability interval); HAQ, health assessment questionnaire; NMA, network meta-analysis; OR, odds ratio; PsARC, Psoriatic Arthritis Response Criteria; PASI, Psoriasis Area and Severity Index; WMD, weighted mean differences; NA, not applicable significant result based on 95% CrI. +Average results were used in the economic model; the probabilistic sensitivity analysis used a beta distribution. *Average results were used in the economic model; the probabilistic sensitivity analysis used a normal distribution. Results for direct, fixed-effect meta analysis for PASI 70/75/90 are reported in Additional files 6, 7 and 8.
\